These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 15842525

  • 1. Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes.
    Lindsay JR, Duffy NA, McKillop AM, Ardill J, O'Harte FP, Flatt PR, Bell PM.
    Diabet Med; 2005 May; 22(5):654-7. PubMed ID: 15842525
    [Abstract] [Full Text] [Related]

  • 2. Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in Type 2 diabetes.
    Cuthbertson J, Patterson S, O'Harte FP, Bell PM.
    Diabet Med; 2009 Jun; 26(6):649-54. PubMed ID: 19538242
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
    Langley AK, Suffoletta TJ, Jennings HR.
    Pharmacotherapy; 2007 Aug; 27(8):1163-80. PubMed ID: 17655515
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects.
    Dai H, Gustavson SM, Preston GM, Eskra JD, Calle R, Hirshberg B.
    Diabetes Obes Metab; 2008 Jun; 10(6):506-13. PubMed ID: 18284437
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
    Campbell RK.
    Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
    Irwin N, McClean PL, Flatt PR.
    J Pept Sci; 2007 Jun; 13(6):400-5. PubMed ID: 17486662
    [Abstract] [Full Text] [Related]

  • 14. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
    Svendsen PF, Nilas L, Madsbad S, Holst JJ.
    Metabolism; 2009 May; 58(5):586-93. PubMed ID: 19375579
    [Abstract] [Full Text] [Related]

  • 15. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
    Diamant M, Bunck MC, Heine RJ.
    Ned Tijdschr Geneeskd; 2004 Sep 25; 148(39):1912-7. PubMed ID: 15495988
    [Abstract] [Full Text] [Related]

  • 16. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?
    McIntosh CH, Demuth HU, Pospisilik JA, Pederson R.
    Regul Pept; 2005 Jun 15; 128(2):159-65. PubMed ID: 15780435
    [Abstract] [Full Text] [Related]

  • 17. Incretins and other peptides in the treatment of diabetes.
    Todd JF, Bloom SR.
    Diabet Med; 2007 Mar 15; 24(3):223-32. PubMed ID: 17263764
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.